Posted on April 10, 20264/10/26
Stay Ahead of Change with NAVLIN Daily’s Global Policy Watch
Posted on March 9, 20263/9/26
Key Implications of Recent U.S. PBM Reforms
Posted on January 14, 20261/14/26
NAVLIN Daily 2025 Round-Up: The Pricing and Policy Trends Redefining Market Access
Posted on December 10, 202512/10/25
Predicting PICOs for EU HTA: The Validated PICO Planner Approach Based on Retrospective Analysis
Posted on September 30, 20259/30/25
Strategic PICO Planning: Navigating Oncology Markets with NAVLIN by EVERSANA
Posted on September 30, 20259/30/25
Strategic PICO Planning: Enhancing Early-Phase Development for Market Access
Posted on September 10, 20259/10/25
The Evolution of the 340B Rebate Model: Maintaining Patient Access while Minimizing Duplicate Discounts
Posted on September 10, 20259/10/25
2026 CMS Proposed Rule: BFSF Changes and Potential Risks for Pharma Manufacturers
Posted on September 10, 20259/10/25
Navigating OBBBA: Why a Strong GP Team is Essential for Pharma Compliance
Posted on August 22, 20258/22/25